Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
916 results about "Cervical ca" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Uterine cervical cancer computer-aided-diagnosis (CAD)
Owner:STI MEDICAL SYST
Method and Devices for Screening Cervical Cancer
ActiveUS20080262384A1Bioreactor/fermenter combinationsBiological substance pretreatmentsCancer cellAnalysis method
The present invention provides multi-parameter analysis methods for determining the presence or absence of pre-cancerous or cancerous cells in a cervical sample and for screening cervical abnormality in a cervical sample. The invention also provides an apparatus and automated methods for screening cervical abnormality in a sample. The invention further provides a sampling device and a sample collection assembly for collecting cell samples, including cervical samples.
Owner:SOUTHWEST RES INST
Biological compositions and methods for treatment of cervical cancer
The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with cervical cancer. The biological compositions can be used to retard the growth of cervical cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.
Owner:ULTRA BIOTECH
Cap-pap test
InactiveUS6143512ABioreactor/fermenter combinationsBiological substance pretreatmentsCervical Pap TestAcid phosphatase
The CAP-PAP Test is a double-staining, single-slide microscopic method. An in vitro diagnostic medical device for manual and automatic staining and interpreting of the Pap smear for cervical cancer screening, cervical dysplasia and for follow-up therapy can be developed using this double-staining, single-slide microscopic method. Abnormal cervical cells are labeled with an intracellular acid phosphatase derived pigment (azo-dye) to improve visibility of abnormal cervical cells on conventionally stained Pap smears. The enzyme marker improves human perception and / or sensitivity of automatic instruments when distinguishing cell a abnormality and interpretation of Pap smears. Increased accuracy of CAP-PAP-vs-Pap test is expected to reduce false negative readings of the conventional Pap test. A rapid manual version of the test that is low cost, does not require additional personnel training and is instantly applicable in all cytopathology laboratories is provided. The invention further provides a diagnostic kit, an automatic stainer and an automatic evaluation device for performing the double-staining, single-slide microscopic method.
Owner:MARKOVIC NENAD +1
SgRNA combined with immunogene to inhibit high risk HPV expression, gene knockout vector thereof, and application of sgRNA and vector
ActiveCN105821040AImprove targetingGrowth inhibitionOrganic active ingredientsGenetic material ingredientsWilms' tumorCas9
The invention provides an sgRNA combined with immunogene to inhibit high risk HPV expression, a gene knockout vector thereof, and an application of the sgRNA and the vector. The sgRNA sequences of a human papilloma virus 16 type gene suitable for CRISPR-Cas9 targeting editing and a human PD-1 gene are selected, and the plasmid vector of the sgRNA and a CRISPR-Cas9 nuclease gene expression vector are transferred to HPV16+ human cervical carcinoma cells and HPV16+ transplantation tumor-bearing mice, and can obviously inhibit HPV16 expression and inhibit tumor growth. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, high CRISPR-Cas9 knockout efficiency, accurate targeting splicing of high risk HPV16 type and PD-1 genes, efficient reduction of the expression of the high risk HPV16 type gene, and obvious inhibition of the tumor growth through combined application.
Owner:李旭
CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
InactiveUS20060182763A1Peptide/protein ingredientsViral antigen ingredientsHuman papillomavirusDendritic cell
The present invention is directed to the examination of the pattern of immunodominant CD8 T cell epitopes in the E6 and E7 protein of Human Papillomavirus (HPV) and its further characterization in terms of its amino acid sequence and HLA restriction. These epitopes are identified based on their ability to induce strong CD8 T cell response and therefore, are important as sources of antigens for dendritic cell immunotherapy to treat cervical cancer. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of HLA types so that they can be used in concert to develop a preventative vaccine, which can be used for general population.
Owner:BIOVENTURES LLC
Application of N-(thiofuran-2) pyrazolo (1, 5-a) pyridine-3-formanides compounds for preparing antineoplastic
The invention searches the novel micromolecule inhibitor pyrazolo (1, 5-a) miazines compounds of cyclin-dependent kinase CDK9 (cyclin-dependent kinase) through the virtual screening of a computer, biometrically measures activity thereof, and validates interaction mechanism. The invention specifically comprises the following steps: the three-dimensional crystal conformation of the cyclin-dependent kinase family member CDK9 is obtained in a way of homology modeling; and micromolecule three-dimensional database is screened with DOCK (molecular docking). The invention uses a MTT tumor cell growth inhibition test to biometrically measures the activity of the selected compounds, researches the selected compounds pyrazolo (1, 5-a) miazines with high activety in a way of molecular mechanism, validates the inhibiting effect of the compounds to the activity of CDK9 kinase, and clarifies the interaction mechanism of the compounds for inhibiting the external activity and the molecule of various malignancies such as lung cancer, osteosarcoma, oophoroma, cervical carcinoma, breast cancer, etc.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
DNA detection and analysis method based on Cas9 nuclease and application thereof
ActiveCN108192956AImprove featuresHigh sensitivityMicrobiological testing/measurementNucleic acid detectionTyping
The invention provides a DNA detection and analysis method based on Cas9 nuclease and application thereof. The method comprises the following three steps: (1) carrying out PCR amplification on targetDNAs; (2) treating a PCR amplification product by using a CAT method; and (3) carrying out PCR amplification with DNAs treated by using the CAT method as a template. The method can successfully detectL1 and E6 / E7 genes of HPV16 and HPV18 in human cervical carcinoma cells. According to the invention, the method successfully avoids current key bottleneck problems in nucleic acid hybridization, designing of specific PCR primers and the like in the fields of nucleic acid detection and typing.
Owner:SOUTHEAST UNIV
Selective Reaction Monitoring (SRM) Derived Protein Profiles for Cancer and other Pathologic Entities
InactiveUS20130288233A1Microbiological testing/measurementBiological material analysisProtein proteinSpecific protein
The invention relates to a method of detecting and quantifying small peptides derived from proteins from a range of different clinical samples using the Selective Reaction Monitoring (SRM) profiling technique. By targeting these unique peptides which specifically identify particular proteins, the present invention enables multiple samples to be run in a multiplexed fashion in order to identify, diagnose, quantitate and profile a full range of benign and pathologic entities, including but not limited to, the complete range of cancers and the spectrum of inflammatory diseases, including inflammatory cell typing and bone marrow cell typing. The SRM assay is capable of performing clinical blood typing and it can also act as a diagnostic test to identify women at highest risk for cervical cancer base on Human Papillomavirus (HPV) testing.
Owner:MAP IP HLDG
Methods of diagnosing cervical cancer
The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.
Owner:ARBOR VITA CORP
Colposcopy image-based cervical cancer detection method, device and equipment and medium
InactiveCN108510482AReduce constraintsSegmentation is fast and accurateImage enhancementImage analysisDisease areaNerve network
The invention discloses a colposcopy image-based cervical cancer detection method, device and terminal equipment and a computer readable storage medium. The method comprises the following steps of: ina bidirectional convolutional neural network-based cervical cancer detection model, positioning and extracting a cervical opening position of an obtained colposcopy image so as to generate an ROI image comprising a cervical cancer disease area; extracting a cutting edge of the ROI image through a bidirectional convolutional neural network so as to generate a cut image; and carrying out cancer grade classification on the cut image through a classification convolutional neural network so as to output a cervical cancer lesion grade and then rapidly and correctly obtain a cervical cancer detection result. According to the method, doctors that are lack of experiences can be helped to rapidly judge diseased regions, discover atypical diseased regions and judge the disease degrees and sampling regions, so that help and auxo-action are provided for discovering cervical cancer and precancerous lesions.
Owner:姚书忠 +3
Shorten human papilloma virus 16 type L1 protein
Owner:XIAMEN INNOVAX BIOTECH +1
Simplified thin-layer liquid-based cytology detection method
InactiveCN1967196ACheap methodGood effectMicrobiological testing/measurementSurgical needlesLiquid base cytologyCervical cells
The invention discloses a simple thin liquid-based cytology examine method applied for the gynecological examination, the cervical cancer general examine and the cervical cancer preceding lesion of selected crowd, the steps including: using the cervical cells brush and the scraper to collect samples, put samples in the liquid-based cell preservation solution, add base liquid cell processing solution, oscillate, centrifugally separate, take and discard the supernatant samples liquid, using adding samples gun to assimilate sediment samples, smear, sheet drying, using 95% ethanol marinate or spray for fixed, washing and dyeing. The invention has simple method, small steps, high positive detection rate, low misdiagnosis rate, low cost, and it can effectively eliminate the red blood cells, mucus and other interference components from the cervical cytology detection specimens, with good sheet-producing result.
Owner:绵竹市人民医院
Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
InactiveUS6462064B1Easy to convertCombating the greasy appearance of the skin orBiocideHydroxy compound active ingredientsCancer preventionRetinoid
The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and / or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
Owner:GALDERMA RES & DEV SNC +1
Methods for detecting papillomavirus DNA in blood plasma and serum
InactiveUS7183053B2Assess prognosisAntibody mimetics/scaffoldsMicrobiological testing/measurementDiseaseAlphapapillomavirus
This invention relates to the detection of extracellular papillomavirus DNA in blood plasma or serum from a human or animal. In particular, the invention relates to the detection, identification, evaluation, or monitoring of neoplastic, premalignant or malignant disease associated with a papillomavirus. The invention thereby provides methods for the identification of individuals at risk for, or having, cervical dysplasia, cervical intraepithelial neoplasia, or cervical cancer.
Owner:PENN STATE RES FOUND
Gene, expression vector, expression method, expression cell and application of human papilloma virus (HPV) 16 E7E6 fusion protein
ActiveCN102002105AStrong immunogenicityPreserve antigenicityViral antigen ingredientsGenetic material ingredientsT cell immunityFhit gene
The invention provides a gene, an expression vector, an expression method, an expression cell and an application of a human papilloma virus (HPV) 16 E7E6 fusion protein. In the invention, recombinant adenovirus is adopted to fuse E6 and E7 protein genes which have no converting activity after modification, and the mammalian cell codon optimization and transformation is performed based on the amino acid sequences of the fusion protein to lead the codon to be expressed in the mammalian cells in a high level. In the invention, an E7E6 fusion protein mammalian cell codon optimization gene is designed successfully, the recombinant adenovirus capable of expressing the HPV16 E7E6 fusion proteins in a high level is successfully constructed, has strong immunogenic performance, can induce immunoreaction of specific T cells, and completely protects immune mice from attacking of anti-tumor cells. The invention can be used for searching and developing therapeutic vaccines of cervical cancer.
Owner:中国疾病预防控制中心病毒病预防控制所
Detection primer for methylation degree of related genes of cervical cancer, probe, kit and application thereof
InactiveCN107287294AReliable resultsHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationCervical tissueBiology
The invention discloses a detection primer for methylation degree of related genes of cervical cancer, a probe, a kit and an application thereof. The invention finds that the methylation degree of promoter zones of four genes, namely, PAX1, FAM19A4, PHACTR3 and DAPK in cervical tissue is obviously related to the cervical cancer; the detection primer can be used as a biomarker for assisting in cervical cancer diagnosis; a methylation probe and a non-methylation probe are designed, so that the influence of non-methylation DNA is avoided and the result is more reliable. Compared with the conventional cervical cancer diagnostic method, the method provided by the invention has the advantages of high speed, high sensitivity, high specificity, and the like, can timely diagnose human cervical carcinoma in early stage, can early accurate diagnose the cervical cancer and can avoid the waste of medical resources.
Owner:广州中心法则生物科技有限公司
Preparation of multi-epitope TK-1 antibody, and application of multi-epitope TK-1 antibody in evaluating treatment effect on tumor patient
ActiveCN102516390AHigh purityIncrease productionEgg immunoglobulinsTransferasesAntigenTreatment effect
The invention provides a high-specificity high-sensitivity coordinated compound anti-human-TK1 antibody prepared from an antigenic determinant composed of human cervical cancer cell TK1 monomer N-terminal 23 peptide, C-terminal 20 peptide and C-terminal 28 peptide, and application thereof in tumor diagnosis. The antigenic determinant contains the following amino acid sequences: N-terminal 23 peptide (3-25): CINLPTVLPGSPSKTRGQIQVIL, C-terminal 20 peptide (206-225) CPVPGKPGEAVAARKLFAPQ, and C-terminal 28 peptide (198-225) AGPDNKENCPVPGKPGEAVAARKLFAPQ. The invention also relates to a method for preparing the antibody prepared from the antigen. The antibody kit provided by the invention has the characteristics of high sensitivity, high specificity, low cost and the like. The treatment effect on the tumor patient is evaluated by an enhanced chemiluminescent point blotting detection method, immunohistochemical detection and the detection kit.
Owner:SHENZHEN HUARUI TONGKANG BIOTECHNOLOGICAL
Method for detecting carcinomas in a solubilized cervical body sample
ActiveUS7306926B2Biological material analysisPeptide preparation methodsCervical intraepithelial neoplasiaMultiple Tumor Suppressor-1
The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly directed to a method for detecting cervical carcinomas, cervical intraepithelial neoplasias, or cervical carcinomas in-situ from a solubilized cervical body sample of a human subject, by solubilizing the cervical body sample in a lysis buffer, and determining the overexpression of cyclin dependent kinase inhibitor p16 in the solubilized cervical sample. The invention also concerns a test kit usable for this purpose as well as an in-vitro diagnostic device.
Owner:VENTANA MEDICAL SYST INC
Sandwich type electrochemical immunosensor for simultaneously detecting markers of cervical cancer
ActiveCN103472121ALarge specific surface areaHigh sensitivityMaterial electrochemical variablesCervical caEngineering
The invention relates to an electrochemical immunosensor, and in particular relates to a sandwich type electrochemical immunosensor which is constructed by taking Au-hybridized mesoporous carbon CMK-3(Au@CMK-3) and two electronic mediators, namely neutral red and thionine, as second antibody markers, a preparation method of the sandwich type electrochemical immunosensor, and application of the electrochemical immunosensor, which is prepared by the method, to simultaneous detection on markers of a cervical cancer. The electrochemical immunosensor can be used for simultaneously detecting two samples and overcoming the limitation of a single index, plays an important role in further improvement of the early confirming rate of the cervical cancer, and can be popularized to the field of simultaneous detection on tumor markers of other cancers.
Owner:UNIV OF JINAN
A kind of monoclonal antibody of ap-2alpha and its application in the preparation of medicine for treating cervical cancer
ActiveCN111393525BInhibition of proliferative abilityImprove immune activityBacteriaImmunoglobulins against animals/humansAntiendomysial antibodiesCervical ca
Owner:湖南金朋医疗器械股份有限公司
4-alkyl-2-arylamino-5-(1,2,4-triazole-1-group) thiazole and application thereof to preparation of medicaments for resisting cancer
InactiveCN102675303AAnti-cervical cancerCtiveOrganic chemistryAntineoplastic agentsHydrobromidePhosphate
The invention discloses 4-alkyl-2-arylamino-5-(1,2,4-triazole-1-group) thiazole and salts thereof shown in a formula I, wherein R is selected from H, alkyl groups of C1-C2 and straight-chain alkyl groups or branched-chain alkyl groups of C3-C4; X1, X2, X3, X4 and X5 are selected from hydrogen, alkyl groups of C1-C2, hydroxide group, methoxy group, oxyethyl group, trifluoromethyl, fluorine, chlorine, bromine, nitryl, amino group, acetyl amino group, methanesulfamide, ethoxycarbonyl or carboxyl; and the salts of the 4-alkyl-2-arylamino-5-(1,2,4-triazole-1-group) thiazole are selected from hydrochloride, hydrobromide, nitrate, sulfate, phosphate, mesylate, p-toluene sulfonate, tartrate, lactate or malate. The 4-alkyl-2-arylamino-5-(1,2,4-triazole-1-group) thiazole is applied to preparation of medicaments for resisting cervical cancer or lung neoplasms.
Owner:HUNAN UNIV
CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
The present invention is directed to the examination of the pattern of immunodominant CD8 T cell epitopes in the E6 and E7 protein of Human Papillomavirus (HPV) and its further characterization in terms of its amino acid sequence and HLA restriction. These epitopes are identified based on their ability to induce strong CD8 T cell response and therefore, are important as sources of antigens for dendritic cell immunotherapy to treat cervical cancer. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of HLA types so that they can be used in concert to develop a preventative vaccine, which can be used for general population.
Owner:BIOVENTURES LLC
Cervical cancer postoperative recurrence risk prediction method and system
PendingCN111640509AAchieve the predicted effectAchieve forecastMedical simulationMachine learningDiseaseCervical ca
The invention provides a cervical cancer postoperative recurrence risk prediction method and system, and belongs to the technical field of medicine. The invention provides a prediction model based onmedium-risk pathological factors. The effect of predicting the postoperative disease recurrence risk of a early cervical cancer patient is achieved and the foothold is postoperative disease recurrencerisk assessment of early cervical cancer patients without high-risk pathological factors; therefore, the disease recurrence risk prediction of cervical cancer patients at any time point after the operation can be realized; and meanwhile, two model verification methods of data of a verification group and a machine learning algorithm are used, external verification is performed on the obtained model, and the prediction accuracy of the constructed model is further ensured, so that the method has a good practical application value.
Owner:SHANDONG UNIV QILU HOSPITAL
Truncated human papilloma virus 18 type L1 protein
The invention relates to a truncated human papilloma virus 18 type L1 protein, and viruslike particles consisting of the truncated human papilloma virus 18 type L1 protein, vaccine containing the viruslike particles and the application thereof in preventing cervical cancer.
Owner:XIAMEN INNOVAX BIOTECH +1
Traditional Chinese medicine for treating cervical cancer
ActiveCN103656041AHeavy bleedingWorseAnthropod material medical ingredientsAntineoplastic agentsMyrrhCancer cell
The invention discloses a traditional Chinese medicine for treating cervical cancer, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine is prepared from the following medicinal raw materials by weight: 20g of fried sophora flower, 20g of selfheal, 20g of sculellaria barbata, 20g of oldenlandia diffusa, 15g of pericarpium citri reticulatae viride, 15g of moutan bark, 15g of peach seed, 15g of white paeony root, 15g of turtle shell, 15g of rhizoma cyperi, 15g of poria cocos, 15g of cortex phellodendri, 10g of cassia twig, 10g of angelica sinensis, 10g of mastic, 6g of myrrh, 5 Chinese dates, 10g of coptis chinensis, 6g of scorpion, 10g of centipede and 3g of liquorice. The traditional Chinese medicine can be used for effectively improving the immunity of cervical cancer patients and the body constitution, inhibiting and killing cancer cells, softening and reducing tumors and improving the bearing capacity of the cervical caner patients and is capable of preventing recurrence and metastasis and increasing treatment opportunities.
Owner:启东市丰武农副产品专业合作社
Method of evaluating female genital cancer
InactiveUS20110143444A1Accurate assessmentBiostatisticsBiological testingCervical caHematological test
According to the method of evaluating female genital cancer of the present invention, amino acid concentration data on concentration values of amino acids in blood collected from a subject to be evaluated is measured, and the state of female genital cancer including at least one of cervical cancer, endometrial cancer, and ovarian cancer in the subject is evaluated based on the concentration value of at least one of Thr, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, and Arg contained in the measured amino acid concentration data of the subject.
Owner:AJINOMOTO CO INC
Detection and prognosis of cervical cancer
InactiveUS20110189653A1Accurate and effectiveRaise the possibilitySugar derivativesMicrobiological testing/measurementOncologyMethylation
The present invention relates to methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. These methods include determining the methylation status or the expression levels of particular genes, or a combination thereof.
Owner:MDXHEALTH
AP-2alpha monoclonal antibody and application to preparation of drugs for treating cervical cancers
ActiveCN111393525AInhibition of proliferative abilityImprove immune activityBacteriaImmunoglobulins against animals/humansAntiendomysial antibodiesCervical ca
The present invention relates to an AP-2alpha monoclonal antibody and an application to preparation of drugs for treating cervical cancers. The monoclonal antibody has the relatively good cervical cancer cell proliferation inhibiting effect, thereby having the wide application prospect.
Owner:湖南金朋医疗器械股份有限公司
Truncated l1 protein of human papillomavirus type 16
ActiveUS20100255031A1Difficult to applyReduced expression levelBacteriaPeptide/protein ingredientsVirus-like particleCervical cancer
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
Owner:XIAMEN UNIV +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com